COVID-19

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More

Novel Host-Mimetic, Virus Killing Technology Platform SHELTON, CT / ACCESSWIRE / May 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the…

2 years ago

Zomedica Enhances TRUFORMA(R) Platform With Launch of Advanced Canine Cortisol Assay

Improved precision and greater accuracy of heavily used assay strengthens market potential for flagship in-clinic diagnostic platformANN ARBOR, MI /…

2 years ago

BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem

BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa,…

2 years ago

Applied DNA Announces Pricing of $12 Million Public Offering

STONY BROOK, NY / ACCESSWIRE / May 28, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),…

2 years ago

CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK

Phase 2 study to assess updated formulations for improved immune responses of multivalent vaccine candidate against influenza B strainStudy initiated…

2 years ago

Workhorse Health Introduces Innovative Mental Health Services for Ontario’s Caregivers and Their Families

TORONTO, May 28, 2024 (GLOBE NEWSWIRE) -- Workhorse Health is on a mission to bridge the gap in mental health…

2 years ago

Evaxion Announces Business Update and First Quarter 2024 Financial Results

COPENHAGEN, Denmark, May 28, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio…

2 years ago

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

Key Findings: 92.3% Sensitivity for Colorectal Cancer, 82.3% for Advanced Precancerous Lesions Poster presentation showing new data on 690 subjects…

2 years ago

Cosmos Health Receives Additional Delinquency Letter from Nasdaq Regarding Late Filings of Its Forms 10-K and 10-Q

CHICAGO, IL / ACCESSWIRE / May 24, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

2 years ago